High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases.
Alexa N SassonAshwin N AnanthakrishnanPublished in: Digestive diseases and sciences (2021)
The presence of high titers of anti-drug antibodies to IFX is not predictive of treatment failure with adalimumab.